pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Phase 3 · small molecule · Anemia
Dynepo (epoetin delta) is a recombinant erythropoietin (EPO) analog developed by Takeda for the treatment of anemia. The drug belongs to the erythropoiesis-stimulating agent (ESA) class and works by stimulating red blood cell production. Dynepo was approved in the European Union on 29 February 2008 under marketing auth
Internal code SPD490-301
Dynepo (epoetin delta) is a recombinant erythropoietin (EPO) analog developed by Takeda for the treatment of anemia. The drug belongs to the erythropoiesis-stimulating agent (ESA) class and works by stimulating red blood cell production. Dynepo was approved in the European Union on 29 February 2008 under marketing authorization holder Shire Pharmaceutical Contracts Limited (EMEA/H/C/000372). However, the product was subsequently withdrawn from the EU market. Takeda's Phase 3 trial SPD490-301 (NCT00450333) was terminated, with the latest milestone recorded on 14 June 2021. The program represents a discontinued development effort in a competitive anemia treatment landscape dominated by established ESAs and newer mechanistic approaches. Dynepo's withdrawal reflects the challenging commercial and clinical environment for traditional EPO analogs, particularly following safety concerns and the emergence of alternative therapeutic modalities in anemia management.
Anemia remains a significant clinical burden affecting millions of patients globally, particularly those with chronic kidney disease, cancer-related anemia, and other chronic conditions. The unmet medical need for effective, safe erythropoiesis-stimulating agents continues despite the availability of multiple approved therapies. Dynepo's development and subsequent withdrawal illustrate the competitive pressures in this therapeutic area, where efficacy, safety profile, dosing convenience, and cost-effectiveness are critical differentiators. The anemia market encompasses diverse patient populations with varying etiologies, treatment responses, and tolerability requirements. Takeda's portfolio includes multiple anemia therapies (FERAHEME, OMONTYS), positioning the company as a significant player despite Dynepo's discontinuation. The competitive landscape includes established players such as Amgen (ARANESP), Hoffmann-La Roche (MIRCERA, NEORECORMON), and Teva (EPORATIO), alongside newer agents targeting alternative mechanisms such as HIF pathway inhibitors (EVRENZO) and luspatercept (REBLOZYL). Dynepo's market exit underscores the challenges facing traditional ESAs in maintaining commercial viability and clinical relevance in an evolving therapeutic ecosystem.
Dynepo (epoetin delta) is a recombinant erythropoietin analog classified within the Blood and blood forming organs therapeutic class (ATC B03). The drug is a small-molecule modality erythropoiesis-stimulating agent designed to stimulate red blood cell production in anemic patients. Specific details regarding mechanism of action, molecular target, and route of administration are not yet disclosed in available documentation. Dynepo represents one of several EPO analogs in clinical development and marketed use, competing with established therapies including:
The drug was previously approved in the European Union but has since been withdrawn from the market.
Also known as: anaemia (disease), anemia (disease)
A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.
ClinicalTrials.gov lists 98 registered studies for Anaemia, (AACT aggregate).
Phase breakdown: NA (35), PHASE3 (21), PHASE1 (18), PHASE2 (12), PHASE4 (11), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0002280), NCT00466297, NCT00767702, NCT01043133, NCT01317979, NCT01477281, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, NCT00140517, NCT00238043, NCT00258024, NCT00259142, NCT00276224, Open Targets Platform (CC BY 4.0).
EU Marketing Authorization Granted
Dynepo received European Union marketing authorization as EMEA/H/C/000372 under marketing authorization holder Shire Pharmaceutical Contracts Limited.
Phase 3 Trial Terminated
Takeda's Phase 3 trial SPD490-301 (NCT00450333) was terminated; specific termination rationale not yet disclosed.
The anemia treatment market is highly competitive, encompassing multiple therapeutic classes and mechanisms. Takeda itself markets FERAHEME (ferumoxytol) and OMONTYS (peginesatide), positioning the company as a multi-product competitor despite Dynepo's discontinuation. Established erythropoiesis-stimulating agents include ARANESP (darbepoetin alfa; Amgen), MIRCERA and NEORECORMON (Hoffmann-La Roche), and EPORATIO (epoetin theta; Teva Pharma GmbH). Biosimilar competition has intensified with RETACRIT (epoetin alfa) approval. Newer mechanistic approaches have expanded treatment options: EVRENZO (roxadustat) targets the hypoxia-inducible factor pathway, while REBLOZYL (luspatercept) acts as an erythroid maturation agent. JESDUVROQ and FERACCRU represent additional approved therapies in the anemia space. EPOSTIM's manufacturer is not yet disclosed. The competitive environment reflects a shift toward agents with improved safety profiles, reduced immunogenicity risk, and alternative mechanisms addressing ESA-resistant anemia. Dynepo's withdrawal suggests the drug could not maintain competitive positioning against this diversified therapeutic landscape.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| FERAHEME | Takeda | — | approved |
| OMONTYS | Takeda | — | approved |
| EPORATIO | Teva Pharma GmbH | — | approved |
| EPOSTIM | — | — | approved |
| JESDUVROQ | — | — | approved |
| FERACCRU | — | — | approved |
| ARANESP | Amgen | — | approved |
| MIRCERA | Hoffmann-La Roche | — | approved |
| NEORECORMON | Hoffmann-La Roche | — | approved |
| EVRENZO | — | — | approved |
| REBLOZYL | — | — | approved |
| RETACRIT | — | — | approved |
| VOXELOTOR | — | Hemoglobin HbA positive modulator | Approved |
| TRIAMCINOLONE ACETONIDE | — | Glucocorticoid receptor agonist | Approved |
| SUTIMLIMAB | — | Complement C1s inhibitor | Approved |
| RUXOLITINIB PHOSPHATE | — | Tyrosine-protein kinase JAK2 inhibitor | Approved |
| RAVULIZUMAB | — | Complement C5 inhibitor | Approved |
| PREDNISONE | — | Glucocorticoid receptor agonist | Approved |
| PREDNISOLONE SODIUM PHOSPHATE | — | Glucocorticoid receptor agonist | Approved |
| PREDNISOLONE ACETATE | — | Glucocorticoid receptor agonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: Dynepo received marketing authorization on 29 February 2008 (EMEA/H/C/000372) under marketing authorization holder Shire Pharmaceutical Contracts Limited. The product has since been withdrawn from the EU market. Additional regulatory status in other jurisdictions is not yet disclosed.
United States FDA: Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Dynepo (epoetin delta) is an erythropoiesis-stimulating agent indicated for the treatment of anemia. It works by stimulating red blood cell production in patients with anemia from various causes.
Dynepo received European Union marketing authorization on 29 February 2008 but has since been withdrawn from the market. The drug is no longer commercially available.
Dynepo was developed by Takeda. The marketing authorization holder in the European Union was Shire Pharmaceutical Contracts Limited.
Dynepo is a recombinant erythropoietin analog that stimulates erythropoiesis (red blood cell production). Specific molecular details are not yet disclosed.
Dynepo is classified as a small-molecule erythropoiesis-stimulating agent within the Blood and blood forming organs therapeutic class (ATC B03).
Dynepo's Phase 3 trial (SPD490-301) was terminated on 14 June 2021. The program is no longer in active development.
Takeda conducted Phase 3 trial SPD490-301 (NCT00450333), which was terminated on 14 June 2021. Specific trial details and termination rationale are not yet disclosed.
Dynepo competes with established erythropoiesis-stimulating agents (ARANESP, MIRCERA, NEORECORMON), biosimilars (RETACRIT), and newer mechanistic approaches (EVRENZO, REBLOZYL). Its market withdrawal suggests competitive disadvantages versus these alternatives.
The specific reasons for Dynepo's market withdrawal are not yet disclosed. Factors may include competitive pressures, commercial performance, or safety/efficacy considerations.
Takeda markets FERAHEME (ferumoxytol) and OMONTYS (peginesatide) for anemia treatment. Dynepo has been discontinued and withdrawn.
U.S. FDA regulatory status for Dynepo is not yet disclosed. The drug was approved in the European Union but subsequently withdrawn.
Dynepo is classified within the Blood and blood forming organs therapeutic class (ATC B03) as an erythropoiesis-stimulating agent.
Dynepo received European Union marketing authorization on 29 February 2008 under EMEA/H/C/000372.
The route of administration for Dynepo is not yet disclosed in available documentation.
No. Dynepo's Phase 3 trial was terminated in June 2021, and the product has been withdrawn from the market. No further development is anticipated.
Dynepo competes with ARANESP (Amgen), MIRCERA and NEORECORMON (Hoffmann-La Roche), EPORATIO (Teva), EVRENZO, REBLOZYL, FERACCRU, JESDUVROQ, and RETACRIT, among others.
Dynepo (Epoetin delta) → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Dynepo's termination and market withdrawal reflect Takeda's portfolio rationalization in the competitive anemia therapeutics space. Despite earlier EU approval, the drug could not sustain commercial viability or clinical differentiation. Takeda's continued focus on FERAHEME and OMONTYS suggests these agents offer superior market positioning or safety/efficacy profiles.
Competitive Implications: The anemia market has consolidated around established ESAs and newer mechanistic classes. Traditional EPO analogs face headwinds from biosimilar competition, safety concerns historically associated with ESAs, and the emergence of alternative pathways (HIF inhibitors, erythroid maturation agents). Dynepo's exit removes one competitor but does not materially alter the competitive landscape given the presence of multiple established alternatives.
Future Catalysts: No further development milestones are anticipated for Dynepo. The program is terminated and the product is withdrawn from market.
Expected Milestones: None anticipated.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.